GRACE Study Fact Sheet

If you've been diagnosed with endogenous Cushing syndrome, the GRACE Study may interest you.

The following information is designed to help you understand what the study is all about.

Information for Eligible Participants

What is the purpose of the GRACE Study?

The purpose of the GRACE Study is to evaluate the effectiveness (benefits) and safety (side effects) of an investigational study medicine, relacorilant, in treating participants with endogenous Cushing syndrome, also known as hypercortisolism.

Who is eligible for the GRACE Study?

Eligible participants must meet the following criteria, in addition to other criteria:

- Male or female between the ages of 18 and 80, inclusive
- Diagnosed with endogenous Cushing syndrome
- Willing and able to comply with the study instructions

There are additional eligibility requirements that the study doctor will explain to you.

What treatment is being studied, and how is it being administered?

Relacorilant is an investigational study medicine that is taken orally. Relacorilant works by binding with the cortisol receptors to decrease the effects of too much cortisol, which can include weight gain, muscle weakness, bruising, fatigue, and other symptoms of Cushing syndrome.

Study Design

What should I expect?

The GRACE Study is divided into two parts: (1) the open-label phase and (2) the randomized-withdrawal phase. All study participants will be in the first part, but only some participants will be eligible to continue to the second part. Your study doctor will let you know if you are eligible to continue to the second part.

After you give consent to participate in this clinical research study, the study team will determine if you meet the specific eligibility criteria to participate. If you are eligible, you will enter the open-label phase of the study and receive the investigational medicine, relacorilant.

(continued on back)

CushingResearch.com

grace STUDY

corc027182 GRACE Study Fact Sheet
Trim: 8.5 x 11 | .125" bleed
CMYK | Match PMS 5473 + 5503 + 5483 + 576

If you are eligible for the second part of the study, you will have a 50/50 chance of continuing to receive relacorilant or receiving the placebo. The placebo looks like relacorilant, but it does not contain any active medicine. Neither you nor your study doctor can choose the group you will be in, and neither of you (including the study staff) will know which treatment group you have been assigned to. This is done to ensure the results of the study cannot be influenced by anyone.

If you complete the study, and your study doctor determines that you have benefited from the investigational study medicine, you will have the option to continue receiving treatment in the long-term extension study.



How long will study participation last?

If you are eligible to participate in both parts of the study, your participation could last up to 46 weeks and include approximately 13 visits to the research site.

You may be asked to return to the research site for extra visits at any time during the study if the study doctor decides that extra assessments are needed for your safety.

Where can I learn more about the GRACE Study?

For more information about this clinical research study and the possible risks and benefits of participation, please visit **CushingResearch.com.**

CushingResearch.com

NCT03697109

Corcept THERAPEUTICS

grace STUDY

corc027182 GRACE Study Fact Sheet
Trim: 8.5 x 11 | .125" bleed
CMYK | Match PMS 5473 + 5503 + 5483 + 576